Jinan Qilu Pharma entered a $300 million agreement to acquire greater China rights to an RNAi therapy for hepatitis B developed by Arbutus Bio of Philadelphia . B-729, Arbutus’ lead candidate, is currently in multiple Phase IIa proof-of-concept clinical trials in combination with other approved or investigational agents. Qilu will pay $40 million upfront and make a $15 million investment in Arbutus. It will also be responsible for up to $245 million in milestone payments plus double digit royalties. More details.... Stock Symbol: (NSDQ: ABUS) Share this with colleagues: // //